Clinical Trial Update: Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of HQK-1001 in patients with beta-thalassemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia

Drugs mentioned

• HQK-1001

Snippet

Sponsor: HemaQuest Pharmaceuticals Inc. | Conditions: Beta Thalassemia | Phase 1, Phase 2 | Status: COMPLETED